Correlation of human epidermal growth factor receptor protein expression and colorectal cancer

被引:0
作者
Wen-Juan Yang [1 ]
Xing-Jie Shen [2 ]
Xiao-Xia Ma [2 ]
Zhi-Gang Tan [1 ]
Yan Song [1 ]
Yi-Tong Guo [1 ]
Mei Yuan [3 ]
机构
[1] Department of Emergency, Jinan Central Hospital affiliated Shandong University
[2] Department of Gastroenterology, Jinan Central Hospital affiliated Shandong University
[3] Department of Statistics, the First People’s Hospital of Jining
关键词
Human epidermal growth factor receptor; Colorectal cancer; Immunohistochemistry; BiomarkerTherapy; Case-control study; Meta-analysis;
D O I
暂无
中图分类号
R735.34 [];
学科分类号
100214 ;
摘要
AIM:To investigate the correlation between human epidermal growth factor receptor(HER-2) protein expression and colorectal cancer(CRC) using a casecontrol study and meta-analysis.METHODS:Tumor tissue specimens from 162 CRC patients were selected for the case group.Fifty cases were randomly selected,and normal CRC tissue at least 10 cm away from the tumor margins of these cases was used to generate the control group.The expression of the HER-2 protein in the 162 CRC tissue samples and the 50 adjacent normal mucosa tissue samples was detected via immunohistochemistry.The experimental data were analyzed using SPSS 18.0software,and R software version 3.1.0 was utilized for further verification.RESULTS:The expression of HER-2 protein in the 162 CRC tissue samples was significantly higher than in the normal tissue specimens.The data showed that the expression of HER-2 in CRC was related to the Dukes’ stage,the depth of invasion and lymph node metastasis.The HER-2-positive patients had lower 3-and 5-year OS rates than the HER-2-negative patients,but there was no significant difference.However,there was a statistically significant difference in the 3- and5-year disease-free survival(DFS) rates of HER-2-positive and HER-2-negative patients.The results of the meta-analysis showed that the expression of HER-2in CRC patients was statistically significantly increased over that of healthy people.The 3-year DFS rate in HER-2-positive patients was markedly lower than that in HER-2-negative patients.CONCLUSION:Down-regulation of HER-2 expression might be a dependable strategy for CRC therapy.
引用
收藏
页码:8687 / 8696
页数:10
相关论文
共 15 条
[1]  
Death decoy receptor overexpression and increased malignancy risk in colorectal cancer[J]. Liang Zong,Ping Chen,Da-Xin Wang.World Journal of Gastroenterology. 2014(15)
[2]  
The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies[J] . Sheng-wen Wu,Cong-chao Ma,Yu Yang.Tumor Biology . 2014 (11)
[3]  
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update[J] . M.J. Duffy,R. Lamerz,C. Haglund,A. Nicolini,M. Kalousová,L. Holubec,C. Sturgeon.Int. J. Cancer . 2014 (11)
[4]  
Prognostic role of neutrophil‐to‐lymphocyte ratio in colorectal cancer: A systematic review and meta‐analysis[J] . Mu‐Xing Li,Xue‐Min Liu,Xu‐Feng Zhang,Jian‐Fei Zhang,Wan‐Li Wang,Ying Zhu,Jian Dong,Ji‐Wen Cheng,Zheng‐Wen Liu,Le Ma,Yi Lv.Int. J. Cancer . 2014 (10)
[5]   Quantifying the impact of between-study heterogeneity in multivariate meta-analyses [J].
Jackson, Dan ;
White, Ian R. ;
Riley, Richard D. .
STATISTICS IN MEDICINE, 2012, 31 (29) :3805-3820
[6]   A Method of Moments Estimator for Random Effect Multivariate Meta-Analysis [J].
Chen, Han ;
Manning, Alisa K. ;
Dupuis, Josee .
BIOMETRICS, 2012, 68 (04) :1278-1284
[7]   Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab [J].
Tol, Jolien ;
Dijkstra, Jeroen R. ;
Klomp, Marjolein ;
Teerenstra, Steven ;
Dommerholt, Martin ;
Vink-Borger, M. Elisa ;
van Cleef, Patricia H. ;
van Krieken, J. Han ;
Punt, Cornelis J. A. ;
Nagtegaal, Iris D. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) :1997-2009
[8]  
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial[J] . Wendy S Atkin,Rob Edwards,Ines Kralj-Hans,Kate Wooldrage,Andrew R Hart,John MA Northover,D Max Parkin,Jane Wardle,Stephen W Duffy,Jack Cuzick.The Lancet . 2010 (9726)
[9]   Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers [J].
Marx, Andreas H. ;
Burandt, Eike C. ;
Choschzick, Matthias ;
Simon, Ronald ;
Yekebas, Emre ;
Kaifi, Jussuf T. ;
Mirlacher, Martina ;
Atanackovic, Djordje ;
Bokemeyer, Carsten ;
Fiedler, Walter ;
Terracciano, Luigi ;
Sauter, Guido ;
Izbicki, Jakob R. .
HUMAN PATHOLOGY, 2010, 41 (11) :1577-1585
[10]   Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin [J].
Vlahopoulos, Spiros ;
Gritzapis, Angelo D. ;
Perez, Sonia A. ;
Cacoullos, Nike ;
Papamichail, Michail ;
Baxevanis, Constantine N. .
VACCINE, 2009, 27 (34) :4704-4708